OBJ signs research agreement with GlaxoSmithKline Healthcare

Pharmaceutical giant GlaxoSmithKline Consumer Healthcare has signed a short term arrangement with Leederville-based transdermal drug delivery company OBJ Ltd to carry out studies into the use of its technology on a range of nonprescription applications.

The full text of a company announcement is pasted below

OBJ Limited (ASX: OBJ) wishes to announce that it has entered into a short term arrangement with GlaxoSmithKline Consumer Healthcare (GSK) during which GSK will be funding and carrying out exploratory studies to investigate the potential use of
OBJ's transdermal drug delivery technology, Dermaportation, for a range of nonprescription healthcare applications.

This arrangement follows a small exploratory study with GSK last year which suggested that OBJ's Dermaportation technology may increase delivery of a specific drug through the skin.

OBJ's Dermaportation technology, and its new Enhanced Transdermal Polymer material, enhance transdermal (through the skin) drug delivery. The technology is applicable to a broad range of drugs and drug delivery environments including applications where chemical and other approaches are unsuitable or unreliable.

Transdermal delivery provides a convenient, effective and patient friendly method of drug delivery for both locally acting and systemic drugs.